HIF-1 as a target for drug development.
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
Giaccia
Amato
A
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California 94305-5468, USA.
Siim
Bronwyn G
BG
Johnson
Randall S
RS
D000818:Animals; D002318:Cardiovascular Diseases / Q000235:genetics / Q000628:therapy; D004268:DNA-Binding Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015195:Drug Design; D005786:Gene Expression Regulation; D006801:Humans; D051793:Hypoxia-Inducible Factor 1; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D009369:Neoplasms / Q000235:genetics / Q000628:therapy; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010100:Oxygen / Q000378:metabolism*; D014157:Transcription Factors
D004268:DNA-Binding Proteins; C497442:HIF1A protein, human; D051793:Hypoxia-Inducible Factor 1; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D009687:Nuclear Proteins; D014157:Transcription Factors; D010100:Oxygen